Article Per Year (5 Year)
p-Index From 2020 - 2025
0.947
P-Index
This Author published in this journals
All Journal Jurnal Pendidikan dan Pembelajaran Khatulistiwa (JPPK) Jurnal Farmasi Klinik Indonesia Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) Jurnal Surya Medika Majalah Farmaseutik JFIOnline Indonesian Journal of Global Health research Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice)
Widyati, Widyati
Rumah Sakit Angkatan Laut Dr. Ramelan, Surabaya
Biochemistry, Genetics & Molecular Biology Chemistry Decision Sciences, Operations Research & Management Education Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Mathematics Medicine & Pharmacology Nursing Public Health Other

Published : 12 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Majalah Farmaseutik

 1 
Comparison Among Proton Pump Inhibitor Inducing Pneumonia in Hospital: Narrative Review Sari, Juwita Permata; Nugroho, Agung Endro; Widyati, Widyati
Majalah Farmaseutik Vol 20, No 3 (2024)
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/farmaseutik.v20i3.88612

Abstract

Critically ill patients requiring intensive care unit (ICU) are highly vulnerable to the emergence of stress-related gastrointestinal bleeding, a condition closely associated with unfavorable clinical outcomes. Despite advancements in preventive measures, antimicrobial therapies, and supportive medical care, ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) continue to effect morbidity and mortality rates significantly. Hospital-acquired pneumonia (HAP) is characterized as a form of pneumonia that does not manifest during the period of hospital admission but rather emerges 48 hours or later after the patient has been admitted. In contrast, VAP occurs after 48 hours of having an endotracheal tube in place. Proton pump inhibitors (PPIs) are used prophylactically to manage stress ulcers in critically ill patients. However, recent scholarly literature has drawn attention to a potential link between using acid-suppressing medications and an increased susceptibility to pneumonia. The precise mechanism through which these acid suppressors might elevate the risk of pneumonia remains unclear. The primary objective of this study was to assess the prevalence of pneumonia associated with different types of proton pump inhibitors. We conducted an extensive literature search using keywords such as "(omeprazole or pantoprazole or lansoprazole or esomeprazole or rabeprazole), ICU, Pneumonia" on two prominent electronic databases: Scopus and PubMed. We identified fourteen articles meeting our inclusion criteria, which were categorized into four groups based on the type of proton pump inhibitor: omeprazole, esomeprazole, lansoprazole, and pantoprazole. The results of this narrative review revealed varying risk levels associated with using different proton pump inhibitors for pneumonia. Esomeprazole had the highest risk level, at 48.84%, followed by lansoprazole at 27.85%, omeprazole at 22.5%, and pantoprazole at 19.94%.
THE EFFECT OF FUROSEMIDE IN CRITICALLY ILL ADULT PATIENTS – A NARRATIVE REVIEW Putri, Cyndi Yulanda; Nugroho, Agung Endro; Widyati, Widyati
Majalah Farmaseutik Vol 20, No 3 (2024)
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/farmaseutik.v20i3.88784

Abstract

Background: Fluid overload is the common condition in the critically ill patients. This associated with the increased fluid intake and inadequate elimination. The management of fluid overload is by fluid removal with diuretic. Furosemide is a loop diuretic that frequently used as the initial therapy. However, the utilization of furosemide in the critically ill reminds a polarizing subject. The purpose of this study is to investigate the impact of furosemide on patients who are critically ill. Methods: The inclusion criteria included randomized controlled trials as well as observational cohort studies. The data sources utilized in this study were PubMed, Science Direct, ProQuest, and Cochrane.Results: We included 13 articles, of which 9 articles about generally critically ill patients with or without acute kidney injury (AKI), 2 articles about heart failure, and 2 articles about post operative. The furosemide was effective in generally critically ill patients with or without AKI, it can decrease the fluid balance, weight change, and improves the urine output. Furosemide had no harmful effect on kidney function. However, patients without oliguria were not recommended to receive high dose of furosemide. Critically ill patients with heart failure who received continuous infusion of furosemide were more susceptible to increased diuresis and greater depression of thoracic fluid content (TFC). Furthermore, it might cause the decrease of renal function. When compared to furosemide, continuous veno-venous hemodiafiltration (CVVHDF) was more successful at removing excess fluid, reducing weight, relieving symptoms, and improving hemodynamic and cardiac performance. In post operative patients, furosemide might cause metabolic alkalosis. Urinary electrolyte excretion rates were promptly altered by the use of low dose furosemide.Conclusion: Based on the patient's clinical data, furosemide use should be taken into consideration. In general, furosemide is effective to improve diuresis. Furosemide in the AKI condition with oliguria has beneficial effect. However, in heart failure condition, furosemide might affect renal function. In post operative, it might cause metabolic alkalosis. Further randomized controlled trial (RCT) is required.
Co-Authors Agung Endro Nugroho Arrang, Sherly Tandi Fauzi, Rifani Giyantolin, Giyantolin Harijono, Pandu Ika Puspita Sari Lukman Hakim Putri, Cyndi Yulanda Rahmatullah, Daril Rahmatullah, Daril Regina Regina Sari, Juwita Permata Setiadi, Diga Albrian Setiawan, Stefanie Simorangkir, Timbul Partogi Haposan Soediatmoko, Soediatmoko Subiakto, Yuli Sutapa, Y. Gatot Yakti, Kuntjoro